Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410026 | 1.00 | ERN1 (0.34) | ERN1LGALS3PDK2KDM4EALDH1A1 | |
| SCHEMBL314954 | 0.87 | PDK2 (0.33) | ERN1PDK2PDE4A | |
| SCHEMBL314953 | 0.87 | PDK2 (0.33) | ERN1PDK2PDE4A | |
| SCHEMBL2415869 | 0.85 | PDE2A (0.33) | KCNH2 | |
| SCHEMBL2415867 | 0.85 | PDE2A (0.33) | KCNH2 | |
| SCHEMBL2407848 | 0.83 | CYP17A1 (0.32) | — | |
| SCHEMBL2407847 | 0.83 | CYP17A1 (0.32) | — | |
| SCHEMBL2418141 | 0.82 | GBA1 (0.36) | — | |
| SCHEMBL2411076 | 0.82 | P2RX7 (0.38) | ERN1PDK2KDM4EALDH1A1MAPK1 | |
| SCHEMBL2411069 | 0.82 | P2RX7 (0.38) | ERN1PDK2KDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | ERN1 3197/4885LGALS3 2414/4885PDK2 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.